-
BMC Gastroenterology: Preoperative plateplates can predict the probability of backdos venous complications in liver transplant patients
Time of Update: 2021-01-31
the counter-analysis of therapeutic weighted gravity, the risk of door vein complications was significantly higher in patients in the high plateplate counting group (OR:9.210, 95% CI: 1.907-44.498, p 0.006) and early dysfunction of allogeneic transplantation (OR:2.087, 95% CI: 1.131-3.853, p s 0.019) are more severe.
-
Lancet Haematol: Issue 3 | Set of cell lymphoma self-hematopoietic stem cell transplantation after the use of amine maintenance treatment
Time of Update: 2021-01-31
followed for 38 months (IQR 24-50) after random grouping, and the three-year progress-free survival rate of the amine group was 80% (95% CI 70-87), The observation group was 64% (53-73) (p-0.012; risk ratio 0.51,95% CI 0.30-0.87).
-
Acartini vs. Ibtini treatment CLL head-to-head trial reaches the main therapeutic end point
Time of Update: 2021-01-29
On January 25, AstraZeneca's official website showed that Calquence's Phase III ELEVATE-RR study for adult patients treated with high-risk chronic lymphoblastic leukemia (CLL) had reached the primary endpoint of non-progressive survival.
-
Japan's Ministry of Health, Labour and Labour (MHLW) approved ORLADEYO (Berosty) for preventive treatment of hereditary angioedema
Time of Update: 2021-01-29
pharmaceutical company BioCryst recently announced that Japan's Ministry of Health, Labour and Labour (MHLW) has approved ORLADEYO™ (Belostad) for the prevention of the sale and production of angioedema (HAE) in adults and children over 12 years of age.
ORLADEYO is the first and only preventive HAE drug approved in Japan.
-
Blood: Multiple CRBN variants associated with amine/pomadamine access resistance!
Time of Update: 2021-01-24
Cereblon (CRBN) is an important binding protein for a variety of drugs, including immunomodulation drugs (IMiDs) widely used in myeloma and new CRBN E3 connective enzyme regulators (CELMoDs), as well as certain protein hydrolysis (PROTAC) drugs that are being developed for the treatment of a range of diseases.
-
Cardiovascular health is key to reducing the risk of Alzheimer's disease
Time of Update: 2021-01-24
In a recent study published in plos medicine, edu found that atherosclerosis is not only associated with cardiovascular disease, but is also a risk factor for cognitive decline and dementia, and that maintaining heart health can help delay or prevent Alzheimer's disease.
-
Nat Commun:BRD4 mediated p53 inhibition is a joint therapeutic target for acute myeloid leukemia
Time of Update: 2021-01-24
MDM2 and BET inhibitors combined to enhance the killing of wild TP53 to AML cells Since both drugs can in principle target a wide range of AML molecular subsypes, and both have different effects, the study aims to explore the effects of the combined use of MDM2i and BETi.
-
JCO: Risk of atrial fibrillation and related factors after hematoblast transplantation
Time of Update: 2021-01-24
study aims to assess the rate and risk factors of new atrial fibrillation (AF) after the heterogeneity HCT, as well as the effects of AF on HCT-related prognosmation.
-
European Urology: Quantitative and qualitative analysis of liquid biopsies to guide clinical decision-making in prostate cancer
Time of Update: 2021-01-24
a new study published today in European Urology reviews current knowledge of blood-based liquid biopsy components, their impact on PC clinical decision-making, the opportunity to accelerate precision medicine, and the challenges of implementing such tests in clinical practice.
-
Blood: Extracellulation histogen can replace clotting enzyme primary initiation to promote in-vascular clotting!
Time of Update: 2021-01-24
in critical diseases, extensive cell damage releases histogens into the bloodstream, which can increase the production of clotting enzymes and lead to DIC, but its molecular mechanisms are unclear.
data suggest that histogen-induced phospholipid-free alternative clotting enzymes can lead to in-blood clotting, revealing new molecular mechanisms for clotting enzyme production and DIC.
-
FDA approves Pfizer's new adaptation certificate for ALK-ALK inhibitor kerazine: ALK-positive interdational degenerative large cell lymphoma
Time of Update: 2021-01-24
121 patients were selected for the trial, including 26 children with relapsed/recurring, systemic ACL-positive ALCL who had received at least one previous systematic treatment.
-
NEJM: New use of old drugs - Sigletin can reduce the risk of acute graft anti-host disease after hematopoietic stem cell transplantation
Time of Update: 2021-01-24
Acute graft anti-host disease (GVHD) is a common complication after hematopoietic stem cell transplantation (HSCT), resulting in an increased risk of adverse prognosis in patients.
-
Plos Med: Kafazomi plus lanadamide and tessamide and cyclophosphamide are used as pre-transplant induction chemotherapy effects and safety for multiple myeloma
Time of Update: 2021-01-24
34.5 months after the mid-level follow-up, the PFS in the KRdc group was significantly longer than in the Tdc/Rdc control group (risk ratio of 0.63, 95% CI 0.51-0.76).
PFS in patients treated with KRdc was not yet assessed, compared with 36.2 months in the Tdc/Rdc control group.
-
Blood: Very low-risk ALL children with low-intensity induced chemotherapy can get a good prognostic!
Time of Update: 2021-01-24
present, it is mainly based on the induced treatment of the 19th day of symptoms and minimum residual lesions (MRD) level of the combined performance of 0.01%, to choose low-intensity treatment can achieve good results in patients.
-
IBD: Taking aspirin daily does not affect the clinical efficacy of patients with inflammatory bowel disease
Time of Update: 2021-01-22
BACKGROUND: Although several studies have confirmed a correlation between the use of nonsteroidal anti-inflammatory drugs and the onset of inflammatory bowel disease (IBD), little is known about the impact of daily aspirin on clinical outcomes in IBD patients.
-
JAMA Netw Open: Are blood CD4 plus T cell counts and viral loads associated with cognitive impairment risk in HIV patients?
Time of Update: 2021-01-22
dVL is associated with a smaller sea mass (d s 0.17; P = .005); In participants treated with cART, dVL was also associated with a smaller amygdala volume (d s 0.23; P = 04)。 the relationship between cortical volume and CD4-T cell count and detectable viral load during scanning, this analysis demonstrates the feasibility and usefulness of a global cooperative initiative to understand the neurological characteristics of HIV infection.
-
Clin Nutrition: Longitudinal changes in body composition in patients with peritoneal dialysis are associated with all-cause mortality
Time of Update: 2021-01-22
, however, ltI loss and FTI gain were independent risk factors for all-cause mortality after adjusting demographic, bio-chemical, and cardiovascular parameters.
in patients with PD, vertical changes in LTI and FTI were associated with all-cause mortality, with loss of lean tissue and increased adipose tissue significantly increasing mortality.
-
Ruishun Bio: The first allogeneic DNT cell drug in China to treat relapsed acute myeloid leukemia has been approved clinically
Time of Update: 2021-01-22
is expected to become the world's first treatment r/r AML isomer immunocellular drug RC1012 injection is the core product of Ruishun Bio, the product has been in November 2020 by china's State Drug Administration Drug Review Center clinical trial implied license, to develop adaptive diseases for recurring acute myeloid leukemia, is currently the first approved to carry out registered clinical trials of allogeneic immune cell products.
-
Oncternal Therapeutics has worked with the Karolinska Institute to develop CAR-T and CAR-NK cell therapies targeted at RUR1
Time of Update: 2021-01-16
We look forward to working with Oncternal to develop T-cell and NK cell therapies for ROR1, an effective target for many oncology adaptations," said Dr. James Breitmeyer, President and CEO of Oncternal.
-
The 22-year-old woman was sent to the ICU after a long overdose of milk tea! How harmful is milk tea to people?
Time of Update: 2021-01-16
Recently, a 22-year-old woman in Changsha, Hunan Province, was sent to the ICU for emergency treatment for diabetic ketoacidosis due to excessive daily drinking of milk tea.
